Premium
Efficacy and Safety of Rizatriptan Versus Standard Care During Long‐term Treatment for Migraine
Author(s) -
Block Gilbert A.,
Goldstein Jerome,
Polis Adam,
Reines Scott A.,
Smith Mary E.
Publication year - 1998
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1046/j.1526-4610.1998.3810764.x
Subject(s) - rizatriptan , tolerability , medicine , migraine , adverse effect , nausea , dosing , somnolence , anesthesia , migraine treatment , triptans , randomization , randomized controlled trial , sumatriptan , agonist , receptor
Rizatriptan is a novel, selective 5‐HT 1B/1D receptor agonist with a rapid onset of action after oral dosing for the acute treatment of migraine. We conducted a long‐term (up to 1 year), multicenter, randomized study in 1831 patients treating more than 46 000 attacks to compare the efficacy and tolerability of rizatriptan 5 mg and 10 mg to standard care medications routinely used for the acute treatment of migraine attacks. Both doses of rizatriptan were highly effective, without evidence of tachyphylaxis. Rizatriptan 10 mg was consistently superior ( P <0.05), both to the 5‐mg dose and to standard care, in providing relief in 90% of attacks, with 50% pain‐free by 2 hours after dosing. The most common dose‐related adverse events were nausea, somnolence, and asthenia/fatigue. Based on this large, multicenter, long‐term trial, rizatriptan is an important new oral agent for the acute treatment of migraine.